Pharmaceutical composition for therapy of interstitial cystitis

Abstract

A depressant of capsaicin-sensitive sensory nerve, containing quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a salt thereof as an active ingredient, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and / or abacterial prostatitis.

Description

TECHNICAL FIELD[0001]The present invention relates to a depressant of capsaicin-sensitive sensory nerve, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and / or abacterial prostatitis.BACKGROUND ART[0002]Interstitial cystitis is sterile cystitis that occurs primarily in women and is a disease exhibiting symptoms such as severe pain and urinary frequency, urinary urgency, nocturia, and a sense of suprapubic pressure or pain when the bladder is filled, which is alleviated after urination (Expert Opinion on Invest Drug, 10: p. 521).[0003]The abacterial prostatitis is sterile prostatitis that is diagnosed on the basis of white blood cell counts and quantitative determination of bacteria in urine specimens according to the disease classification of Drach, et al. (1978), and is thought as a variant of condition of interstitial cystitis (Expert Opinion on Invest Drug, 10: p. 521).[0004]Hypersensitive disorder of the lower urinary...

AI Technical Summary

Benefits of technology

The present invention is about a new compound, quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (Compound A), and its use as a therapeutic drug for urogenital diseases such as interstitial cystitis, hypersensitive disorder of the lower urinary tract, and abacterial prostatitis. Compound A has been found to have a depressant effect on capsaicin-sensitive sensory nerves, which are involved in pain and symptoms such as urinary urgency. The invention is based on the discovery that Compound A is effective in treating these diseases by inhibiting the action of muscarine M3 receptors and has a high potency for inhibiting the bladder's sensory nerves. The invention provides a pharmaceutical composition containing Compound A as the active ingredient for the treatment of urogenital diseases.

Problems solved by technology

However, the improvement of pain of urogenital diseases exhibiting painful symptoms is neither indicated nor disclosed, and the therapy of specific diseases such as interstitial cystitis, hypersensitive disorder of the lower urinary tract, and abacterial prostatitis is not disclosed at all.

Images